Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.47 |
| ▸ | CA4 | P22748 | 1/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 5/20 | 0.45 |
| ▸ | NAALAD2 | Q9Y3Q0 | 3/20 | 0.45 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MME | P08473 | 3/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | MMEL1 | Q495T6 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24120783 | 0.86 | MAPT (0.43) | CA2CA4FOLH1NAALAD2RIMKLA | |
| SCHEMBL14177314 | 0.84 | FOLH1 (0.60) | CA2CA4FOLH1NAALAD2RIMKLA | |
| SCHEMBL13287551 | 0.80 | FOLH1 (0.74) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL18145912 | 0.80 | FOLH1 (0.74) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL26518658 | 0.79 | FOLH1 (0.55) | FOLH1NAALAD2RIMKLAMAPT | |
| SCHEMBL19360075 | 0.79 | FOLH1 (0.44) | CA2CA4FOLH1NAALAD2RIMKLA | |
| SCHEMBL8605787 | 0.78 | FOLH1 (0.54) | CA2CA4FOLH1NAALAD2RIMKLA | |
| SCHEMBL8605785 | 0.78 | FOLH1 (0.54) | CA2CA4FOLH1NAALAD2RIMKLA | |
| SCHEMBL23734484 | 0.77 | FOLH1 (0.72) | FOLH1NAALAD2RIMKLAMAPTMME | |
| SCHEMBL22303240 | 0.77 | MAPT (0.42) | FOLH1NAALAD2RIMKLAMAPTMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3397968-B1 | UREA-BASED PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITORS FOR IMAGING AND THERAPY | FIVE ELEVEN PHARMA INC (US) | 2021-09-29 | — | — | EP | disclosed |
| US-20210220493-A1 | PSMA TARGETED RADIOHALOGENATED UREA-POLYAMINOCARBOXYLATES FOR CANCER RADIOTHERAPY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-07-22 | — | — | US | disclosed |
| EP-3319643-B1 | HBED-BISPHOSPHONATES AND RADIOMETAL CONJUGATES THEREOF, USEFUL AS THERANOSTIC AGENTS | FIVE ELEVEN PHARMA INC (US) | 2020-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210220493-A1 | PSMA TARGETED RADIOHALOGENATED UREA-POLYAMINOCARBOXYLATES FOR CANCER RADIOTHERAPY | PSMA1, PSMA3, PSMA2 | CA2 2010/4885CA4 1067/4885FOLH1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.